Tg Therapeutics (TGTX) Other Accumulated Expenses (2018 - 2026)

Tg Therapeutics' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $596000.0 for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 79.78% year-over-year to $596000.0; the TTM figure through Mar 2026 stood at $596000.0 (down 79.78% YoY), while the FY2025 annual figure was $2.1 million, down 54.1% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $596000.0, down from $2.1 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $4.6 million in Q4 2024, with the low at $596000.0 in Q1 2026.
• The 5-year median for Other Accumulated Expenses is $1.9 million (2022), against an average of $2.2 million.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses sank 93.61% in 2022, then jumped 232.84% in 2024.
• Tg Therapeutics' Other Accumulated Expenses stood at $1.2 million in 2022, then advanced by 26.52% to $1.5 million in 2023, then soared by 212.85% to $4.6 million in 2024, then plunged by 54.1% to $2.1 million in 2025, then tumbled by 71.94% to $596000.0 in 2026.
• Business Quant data shows TGTX's Other Accumulated Expenses at $596000.0 in Q1 2026, $2.1 million in Q4 2025, and $2.0 million in Q3 2025.